Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

One man's trash may be another man's treasure, but dumpster diving when investing carries risks. You have to wade through a ...

With macroeconomic uncertainty swirling, Bank of America analyst Anthony Cassamassino warns that a worst-case scenario could ...

The results exceeded Wall Street targets and pushed the U.S. drugmaker's shares up 11% in premarket trading, while dragging ...

PARIS – Amid the luxury slowdown, Hermès International showed continued strength with sales in the first quarter up 7 percent ...

Eli Lilly shares slid 8.2% last month thanks to tariff tremors and Medicare’s snub of pricey weight-loss drugs. The company’s ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity after venturing into the biggest and ...

Pfizer has discontinued its experimental weight-loss pill danuglipron after a trial patient experienced potential ...

Pfizer on Monday said it has discontinued development of experimental weight-loss pill danuglipron after a trial patient experienced potential drug-induced liver injury which resolved after the ...